Completion of Funding Package

Deltex Medical Group PLC
18 April 2008

                            Deltex Medical Group plc

  £2 million funding package agreed for expansion of US and German operations

18 April 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, today announces that it has
secured £2.0 million of new finance to fund expansion of its sales and marketing
operations in the USA and Germany.

Deltex Medical announced its preliminary results for the year ended 31 December
2007 on 7 April 2008 and stated that it had accepted an irrevocable undertaking
from Nexus Medical Partners II, LP ('Nexus') to subscribe for 3,030,303 ordinary
shares of 1p each at a price of 22.0p per share. Since then the Company has
continued its discussions both with Nexus and with Medicis Capital Partners GmbH
('Medicis'), a German affiliate of Nexus. As a result the Company has accepted
further irrevocable undertakings from Nexus to subscribe for an additional
336,701 new ordinary shares of 1p each at 22.0p per share (increasing their
total subscription to 3,367,004 shares) and from Medicis to subscribe for
3,469,388 new ordinary shares of 1p each at 24.5 p per share.

These undertakings to subscribe for a total of 6,836,392 new ordinary shares of
1p each (the 'New Ordinary Shares') at 22.0p and 24.5p to raise £1,590,741
before expenses are subject to approval by shareholders at the Company's
forthcoming Annual General Meeting and assumes no material adverse changes in
the Company's business prior to the new ordinary shares being issued. Ed Snape,
a non-executive director of Deltex Medical, is also a principal of Nexus Medical
Partners.

The New Ordinary Shares will rank pari passu with the existing issued shares of
the Company. Following the issue of the New Ordinary Shares the Company will
have a total of 99,738,045 ordinary shares in issue. This total includes an
allotment of 413,746 new ordinary shares which are also subject to approval at
the next general meeting of the Company as announced on 25 January 2008.
Application has been made for these shares to be admitted to trading on AIM and
dealings are expected to commence on 14 May 2008.

In addition to their investment in New Ordinary Shares, Nexus has agreed to lend
approximately £259,259 to the Company's US subsidiary by way of an unsecured
loan note repayable after five years. Interest on the loan note is to be charged
at 4% per annum with all interest rolling up for settlement on redemption.

In addition to their investment in New Ordinary Shares, Medicis has agreed to
lend approximately £150,000 to the Company's German subsidiary by way of an
unsecured loan note repayable after five years. Interest on the loan note is to
be charged at 6% per annum with all interest rolling up for settlement on
redemption.

The unsecured loan from Nexus will be denominated in US dollars, with the loan
from Medicis in Euros and the exact amounts will be such that Nexus's total new
investment in Deltex Medical will be $2,000,000 and Medicis's €1,250,000 on the
date of investment.

The total funds from Nexus and Medicis to be invested are specifically for use
in expanding the US and German markets respectively, including the hiring of
additional management and field staff in key locations to manage and support the
growing demand for the Company's products. The US funds are managed by Nexus on
behalf of a US State Government to promote economic development.

Deltex Medical's Chief Executive, Andy Hill commented:

'The USA and Germany are two of the largest potential markets for the CardioQ
and we have established solid bases in each of them over the last few years.
This new funding package is on terms designed to attract us to develop our US
and German operations and allows us to push forward more quickly with our
focused expansion plans.'


For further information, please contact:-

Deltex Medical Group plc                     01243 774 837
Nigel Keen, Chairman                         [e-mail]
Andy Hill, Chief Executive                   [e-mail]
Ewan Phillips, Finance Director              [e-mail]

Gavin Anderson & Company                     0207 554 1400

Deborah Walter                               [e-mail]
Robert Speed                                 [e-mail]
Stuart Macaulay                              [e-mail]

Charles Stanley Securities                   020 7149 6000
(Nominated Adviser)
Philip Davies                                [e-mail]
Russell Cook                                 [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
            DRNFGRZM